Portola will start phase-3 trial of Betrixaban in VTE prevention of acute hospitalized patients, according to JPM presentation: http://finance.yahoo.com/news/Portola-J-P-Morgan-Healthcare-iw-1377695786.html?x=0 Good luck with that! This is an indication where Xarelto and Eliquis both failed in phase-3 trials (#msg-61803303, #msg-68938689). Betrixaban used to partnered with MRK, but MRK dumped the program in early 2011 (#msg-61300408). p.s. I was bearish on Betrixaban five years ago (#msg-21106352) and not much has changed since then, IMO.